Ovarian Carcinoma Clinical Trial
Official title:
Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management
Prospective, monocentric study evaluating the presence of sarcopenia prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management.
Prior to carrying out the research, the informed consent of the person must be obtained after being informed of the purpose of the research, its conduct and duration, benefits, potential risks and constraints of the study. Before inclusion,all eligibility criteria will be verified. Sarcopenia in patients with inoperable, high-grade epithelial ovarian carcinoma will be evaluated at different times: - before treatment, in the 30 days prior to their inclusion in the study, - after 3 neoadjuvant chemotherapy cycles, - after 3 adjuvant chemotherapy cycles, - 9 months after surgery. The reference detection method is by CT-scan. This will be combined with a bone mineral density test which is also a way of entering into a more specific approach to sarcopenia screening. On inclusion, the patients will receive optimised treatment by nutritional monitoring and adapted physical activity (APA) in addition to follow-up for sarcopenia. This follow-up by a dietician and a physical fitness trainer will be recorded at each neoadjuvant chemotherapy session. Dietary advice will be given each time along with personalised advice if weight loss were to be observed. If undernutrition or a foreseeable risk of undernutrition are diagnosed, parenteral nutrition will be prescribed by the oncologist, the anaesthetist or the surgeon. The objective of APA is to prevent the onset or aggravation of disease, to increase patient autonomy and quality-of-life, or even to help them return to social activities. Respiratory preparation will also be offered to increase the patient's respiratory capacity in view of surgery, with exercises to be done using a respiratory training device. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05494580 -
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02530606 -
Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer
|
N/A | |
| Active, not recruiting |
NCT02244502 -
Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
|
Phase 1/Phase 2 | |
| Terminated |
NCT02218502 -
Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses
|
N/A | |
| Terminated |
NCT01936974 -
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
| Completed |
NCT00756847 -
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02878980 -
An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
| Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04251052 -
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
|
N/A | |
| Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
| Completed |
NCT00989651 -
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05591560 -
Itraconazole in Advanced Ovarian Cancer
|
N/A | |
| Completed |
NCT01481701 -
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
|
Phase 2 | |
| Completed |
NCT00181701 -
Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin
|
Phase 2 | |
| Terminated |
NCT00047632 -
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
|
Phase 3 | |
| Recruiting |
NCT03302884 -
Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma
|
N/A | |
| Completed |
NCT02166905 -
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 |